Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 4.40B P/E - EPS this Y 109.10% Ern Qtrly Grth -
Income -73.52M Forward P/E 85.85 EPS next Y 350.00% 50D Avg Chg -2.00%
Sales 287.61M PEG - EPS past 5Y - 200D Avg Chg 102.00%
Dividend N/A Price/Book 8.70 EPS next 5Y - 52W High Chg -17.00%
Recommedations 2.50 Quick Ratio 5.52 Shares Outstanding 279.35M 52W Low Chg 376.00%
Insider Own 0.32% ROA -8.49% Shares Float 247.85M Beta 1.17
Inst Own 86.52% ROE -19.88% Shares Shorted/Prior 20.61M/20.64M Price 17.17
Gross Margin 26.42% Profit Margin -25.56% Avg. Volume 6,453,858 Target Price 25.50
Oper. Margin 22.88% Earnings Date Feb 28 Volume 5,319,396 Change -5.89%
About ImmunoGen, Inc.

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

IMGN Chatroom

User Image FE123 Posted - 3 days ago

$IOVA No Insider Buys from WR Tonight, Buyout Tuesday is still Possible! Also $IMGN had a very high Short Interest Before their Buyout! Give me $35 on Tuesday!!

User Image Ripper0811 Posted - 6 days ago

$VKTX @ChappiesWorld Hey Moron, ChoppyDick, This guy TrustButVerify was heavy into $IMGN and I took a chance on it because his DD was so spot on with mine. Admired that he put in the work to do that for all to see. And I made a million in my IRA. Tax fuckn free. So till you have something more than a Snotty punk's whine on anything, STFU!

User Image FE123 Posted - 1 week ago

$IOVA No Additional Buys from WR so far, Buyout Monday for $32 like $IMGN possible!

User Image StockednLoaded Posted - 1 week ago

$IOVA $ABBV paid $10.1B for $IMGN. After receiving accelerated approval to treat adv epithelial ovarian c*ncer, Elahare earned Revenues of: 1st Full Q: 46M Rev 2Q: 76M 3Q: 107M 4Q: 123M 10.1B acquisition, Trailing 348M sales = some combination of: 29x trailing 12m Sales (if you assume no value to pipeline). Iova has guided: More than 100 patients treated or enrolled in less than 3 months as well as expressed another 60 are in screening. Since approval Amtagvi has already moved to 2L Adv Melanona. Sales have been guided for MoM growth. Ignoring that and just using roughly 600 patients for first 4 full quarters and 900 patients for 2025 (conservative growth due to ex-US coming online ~Q2) 900 patients FY ‘25 * (515k + 90kproleukin), let’s assume 550k total to account for potential dropouts/discounts = $495M rev 29x those sales (if you ignore pipeline) would be 14.35B. Advanced lung 👀 1L Adv Melanoma 👀 Accretive-to-EPS 1.3B NOL 👀 20% short @3B 🤔

User Image FE123 Posted - 2 weeks ago

$IOVA Letting the Shorts Cover for the Buyout Next Week! Give me $32 like $IMGN

User Image moonbear Posted - 2 weeks ago

$TPST I'm comfortable holding. The drop is no biggie. Went through all this with $IMGN last year

User Image Quantumup Posted - 2 weeks ago

BofA initiated $STRO Buy/$12 Luvelta (FolRa ADC), is in a Ph3 trial in prev treated platinum-resistant ovarian cancer (PROC) pts; BofA thinks luvelta has the pot to treat up to 80% of PROC pts, a sig improvement over the 30% eligible4 $IMGN $ABBV's Elahere (approved FolRa ADC):

User Image GPS_OS_21_vs_SOC_5 Posted - 04/30/24

$SLS $BMY and $MRK are going to bidding against each other. Gps +Keytruda achieved an OS of 18.4 months for Advanced Platinum Refractory Ovarian cancer patients. Elahere $IMGN just got approved for 16.46 months of os and was bought for $10.1B Gps + Opdivo $BMY achieved OS rate of 47% at 3 years for Ovarian Cancer patients, an earlier setting, SOC is 10-25%.

User Image GPS_OS_21_vs_SOC_5 Posted - 04/29/24

$IMGN $BMY $MRK $SLS

User Image Night_Owl_Biotech Posted - 1 month ago

SWTX's CEO is adamant Ogsiveo is a $1B/year therapy just in the US. If SWTX's CEO is right "AND" Ogsiveo's non-US opportunity is 50% of the US then Ogsiveo could be a $1.5B/year therapy at peak. B of A analyst Alec Stranahan pegs peak ReNeu sales at $1.5B/year. If SWTX's CEO "AND" the B of A analyst are right then $SWTX sales could hit $3B at peak (assumed within 10 years)? The attached graph compares SWTX analyst consensus revenue estimates (thru FY2028 per Seeking Alpha as of Feb. 2024 thru peak at $3B in FY2035 with 2% increases through FY2040) to Immunogen's revenue forecast through 2040 per Immunogen management. Put simply, if the SWTX estimates are close then SWTX's 2 products could dramatically outpace IMGN product sales. IMGN was acquired for an enterprise value of $9.6B. Both SWTX & $IMGN sell pills that produce, more or less, the same gross manufacturing margins. This is not investment advice. We only suggest you research SWTX for yourself. $XBI

User Image GPS_OS_21_vs_SOC_5 Posted - 1 month ago

$SLS If the imminently due phase 3, Fda Registrational results are positive, and all data points suggest it is, Gps immunotherapy will be worth 10b+. -- Just a fact. SLS current market value $85M $IMGN got bought for $10B just for platinum resistant ovarian cancer results of 16.46 months of os. Gps +keytruda $MRK achieved 18.4 months. Gps will treat 25,000 aml remission patients, 200% to 400%+ increase in overall survival, near 100% quality of life, ease of administration, and manufacture, high margin. Big Pharma will fairly value Gps, even if this short rigged market won't. And $BMY could by Gps right now for a few billion, Just for the Mesothelioma Results - Hysterical, No One But @G_Trade was Posting about this huge news GPS + OPDIVO will be Publishing Trial Results At #ASCO2024

User Image FE123 Posted - 1 month ago

$VKTX Reminds me of $IMGN and huge Call buying before the Buyout few days Later!

User Image GPS_OS_21_vs_SOC_5 Posted - 1 month ago

$SLS Elahere $IMGN was bought for $10.1B after achieving 16.46 months of median Overall Survival for Platinum Resistant Ovarian Cancer patients. Gps + Keytruda achieved Os of 18.4 Months in the same setting. $MRK Keytruda alone was 13 months. https://www.elahere.com/results-with-elahere#overall-survival

User Image GPS_OS_21_vs_SOC_5 Posted - 1 month ago

@jacksparo Unblinded p3 results Imminent / idmc meeting this month, offers an investment opportunity of a lifetime. - all pooled p3 patients, Gps and Bat combined have an os of 16 months - Fda only requires Gps os of 12.6 for approval / its closer to 24 - 25 doctors treating regal patients state, bat os is only 6 months or 6-8 months - Gps achieved a highly statistically significant os of 21 months in the p2 Fact: the last time we were awaiting an idmc update the share price climbed 300% in advance - contemporaneous aml 2nd remission trial data is in from md anderson w 6.5 months of os - gps has increased os 2, 3, 4x in a total of 11 trials - Increased os has been directly correlated w Gps immunotherapy immune responses. $Imgn was a $270m co when it released it p3 data - bought for 10b - Cpxx was a $50m co when it released its p3 aml data, bought for $1.5b 60 days later. - Gps is worth 100x + the current share price ... w an emphasis on the + and the whole ’market’ is about to find out.

User Image GPS_OS_21_vs_SOC_5 Posted - 1 month ago

$SLS Unblinded p3 results Imminent / idmc meeting this month, offers an investment opportunity of a lifetime. - all pooled p3 patients, Gps and Bat combined have an os of 16 months - Fda only requires Gps os of 12.6 for approval / its closer to 24 - 25 doctors treating regal patients state, bat os is only 6 months or 6-8 months - Gps achieved a highly statistically significant os of 21 months in the p2 Fact: the last time we were awaiting an idmc update the share price climbed 300% in advance - contemporaneous aml 2nd remission trial data is in from md anderson w 6.5 months of os - gps has increased os 2, 3, 4x in a total of 11 trials - Increased os has been directly correlated w Gps immunotherapy immune responses. $Imgn was a $270m co when it released it p3 data - bought for 10b - Cpxx was a $50m co when it released its p3 aml data, bought for $1.5b 60 days later. - Gps is worth 100x + the current share price ... w an emphasis on the + and the whole ’market’ is about to find out.

User Image zambono Posted - 1 month ago

@moonbear nice, it went from $4 to $31 within the year $IMGN . People are inpatient, $TPST was 30 cents not too long ago.

User Image GPS_OS_21_vs_SOC_5 Posted - 1 month ago

@OnTheBalance All the Variables and Facts Stack up to a large number of billions: Patent locked down on all Key WT1+ Epitopes - the only true targetable OncoGene for AML - ie once its knocked out, its dead, there is no Mutational burden. Gos Expiry 2035 + orphan + Gps+ restarts the Clock Market Scope for AML 10K 2nd Remission, 15k 1st + Est 75K now in remission right now... CCo published pricing comps starting at $260k Per Patient Per year $2.6B for Cr2 - $3.5B for CR1 + Post ASCT + Additional WT1 Targets. $IMGN Got bought for 10B just for its FRA+ Ovarian Cancer Results, WT1 + OC is bigger and GPs OS is Better. I do not see the board / Ceo Selling for less than $10B or Appx $97 Per Share ALL IN - Includes all Shares. - Then add in 009.

User Image GPS_OS_21_vs_SOC_5 Posted - 1 month ago

$SLS @Wut_About_Bob as a matter of fact in the Ph2 Gps Keytruda $MRK published abstract trial for advanced, platinum resistant/refractroy ovarain cancer patients, the Memorial Sloan Kettering and Merck Doctors said Gps immunotherapy was directly correlated to increased survival, (13 months w Key alone vs 18.4 w Gps - obviously they see Gps working) and Gps would work even better in a Remission maintenance setting - like the current P3, imminently due P3. note: elahere was approved in this same setting proc w 16.4 months of os, $IMGN and got bought for 10.1b. $MRK / $BMY will be paying a premium for a deRisked Gps once the P3 is In, any day now.

User Image Ridiculous78 Posted - 1 month ago

$ALPN Price action is always telling to a buyout.. Writing was on the wall over at $AMAM and $IMGN as well! $JANX could be next 🤔

User Image FE123 Posted - 1 month ago

$IOVA $IMGN Many Similarities, FDA approvals, outstanding shares and now price Pattern! $IMGN after approval went up to $21 back down to $13 and then Buyout for $32 Would definitely like to see $IOVA have more of a Higher Buyout like $IMMU at $88, but we shall see!

User Image GPS_OS_21_vs_SOC_5 Posted - 1 month ago

@bikechain $97 is a 10b ALL IN, Buyout. $IMGN was bought for 10.1B based on Elahere achieving 16.46 months of OS for PROC and Approval. GPs +$mrk achieved 18.4 in the same setting. Just Ovarian cancer is worth 10B.

User Image GPS_OS_21_vs_SOC_5 Posted - 1 month ago

@BigSal69 $SLS -- there are nearly 50 institutional funds currently, with some shares, that are going to be doing the following math, when the P3 confirms Gps efficacy: 10,000 AML CR2 Patients First Fda Approved Indication at $260K per patient, $2.6B TAM - estimated Patient Uptake 70% 75,000 Current AML remission and Post Allo Stem Cell transplant ... all who will benefit from Gps Immunotherapy Compare that - to the current $60m MCAP. 15,000 AML CR1 Patients - Expanded Label 12,000 Platinum Resistant Ovarian cancer 3,000 Mesothelioma $IMGN just got bought for 10.1b based on Elahere P3 OS data of 16 months, Gps + Keytruda is at 18.4 - in a less healthy setting. Massive Upside right now. and the results are Imminently Due.

User Image GPS_OS_21_vs_SOC_5 Posted - 1 month ago

$SLS Price will be climbing every day we wait for the Imminently Due P3 announcement ... and then its lift off ... What is an Immunotherapy that will treat 25,000 AML remission patients worth? -- Its the question the 'market' will be considering. -- Cco published analog pricing comps of $260K minimum -- 260K * 25,000 Just AML maintenance is a $6B TAM for this $64M of short Manipulated Equity Gps achieving statistical efficacy in this firs AML Remission, patient setting then opens the door for many other indications. We already have PH2 Published Gps Keytruda $MRK combination Ovarian Cancer data better (18.4 months of OS ) than a Elahere $IMGN (16.46 Months)that got bought for 10B. Then look at these Gps + Opdivo $BMY Mesothelioma results + 3,000 More Patients. - https://www.asbestos.com/news/2024/01/31/early-vaccine-shows-promise/

User Image Pbake87 Posted - 1 month ago

$XFOR check out $IMGN stock. when they announced the stock inducement award in 2023 Jan 4, the sp blew through the roof. Check it out. this was just announced here AH. $AKBA $ICU

User Image FE123 Posted - 03/29/24

$IOVA this is where $IMGN price was when Buyout was announced for $32 but leaning towards $IMMU price of $88 by year end!

User Image FE123 Posted - 2 months ago

$IOVA If $IMGN was purchased for $32 we are Worth over $50!!

User Image NEWBIGTECH Posted - 2 months ago

$IMGN $BMY $MRK $SLS

User Image DGANG3 Posted - 2 months ago

$IMGN Cashed in and bought IOVA but this company, IMGN, sold their souls and could have been collecting $60-80/sh if they waited 6-8 months for this announcement and sales info like everyone wanted when the sale was announced. I wonder if Eunady has a big job at Abbvie? Sad

User Image GPS_OS_21_vs_SOC_5 Posted - 2 months ago

$IMGN $BMY $MRK $SLS You can Easily See why BMY and MRK will Be in a bidding war for Gps.

User Image GPS_OS_21_vs_SOC_5 Posted - 2 months ago

$IMGN $BMY $MRK $SLS https://www.asbestos.com/news/2024/01/31/early-vaccine-shows-promise/

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Coen Stacy Ann SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER Feb 02 Sell 29.3 4,583 134,282 73,274 02/06/24
Coen Stacy Ann SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER Feb 02 Option 0 14,350 77,857 02/06/24
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Feb 02 Sell 29.3 12,027 352,391 21,039 02/06/24
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Feb 02 Option 0 29,640 33,066 02/06/24
Enyedy Mark J CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Feb 02 Sell 29.28 20,107 588,733 584,397 02/06/24
Enyedy Mark J CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Feb 02 Option 0 51,234 604,504 02/06/24
Lentini Renee VP & PRIN ACCTG OFFI.. VP & PRIN ACCTG OFFICER Feb 02 Sell 29.3 2,631 77,088 14,723 02/06/24
Lentini Renee VP & PRIN ACCTG OFFI.. VP & PRIN ACCTG OFFICER Feb 02 Option 0 8,435 17,354 02/06/24
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Jan 16 Sell 29.64 187,667 5,562,450 3,426 01/18/24
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Jan 16 Option 5.28 187,667 990,882 191,093 01/18/24
Coen Stacy Ann SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER Dec 29 Option 5.32 30,000 159,600 63,140 01/03/24
Lentini Renee VP & PRIN ACCTG OFFI.. VP & PRIN ACCTG OFFICER Dec 22 Sell 29.74 6,548 194,738 8,452 12/27/23
Lentini Renee VP & PRIN ACCTG OFFI.. VP & PRIN ACCTG OFFICER Dec 22 Option 0 15,000 15,000 12/27/23
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Dec 15 Sell 29.4 117,445 3,452,883 2,811 12/19/23
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Dec 15 Option 4.94 117,445 580,178 120,256 12/19/23
Coen Stacy Ann SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER Nov 30 Sell 29.20 3,826 111,719 33,140 12/05/23
Peterson Kristine Director Director Nov 30 Sell 28.9 20,000 578,000 12/05/23
Peterson Kristine Director Director Nov 30 Option 11.59 20,000 231,800 20,000 12/05/23
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Nov 29 Sell 22.81 171,216 3,905,437 2,811 12/01/23
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Nov 29 Option 10.7 171,216 1,832,011 167,235 12/01/23
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Nov 15 Sell 15.85 166,725 2,642,591 2,811 11/17/23
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Nov 15 Option 4.55 166,725 758,599 169,536 11/17/23
Coen Stacy Ann SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER Nov 15 Sell 16.02 108,609 1,739,916 36,966 11/17/23
Coen Stacy Ann SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER Nov 15 Option 6.31 108,609 685,323 115,189 11/17/23
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Nov 07 Sell 16.66 19,517 325,153 2,811 11/08/23
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Nov 07 Option 10.65 19,517 207,856 22,328 11/08/23
Lentini Renee VP & PRIN ACCTG OFFI.. VP & PRIN ACCTG OFFICER Nov 06 Sell 15.29 219,545 3,356,843 11/08/23
Lentini Renee VP & PRIN ACCTG OFFI.. VP & PRIN ACCTG OFFICER Nov 06 Option 7.05 120,528 849,722 219,545 11/08/23
Wallace Richard John Director Director Nov 07 Option 14.70 10,000 147,000 10,000 11/08/23
Goldberg Mark Alan Director Director Oct 30 Option 14.89 20,000 297,800 60,151 11/01/23
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Sep 15 Sell 15.44 192,013 2,964,681 2,811 09/19/23
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Sep 15 Option 3.43 108,668 372,731 194,824 09/19/23
Peterson Kristine Director Director Sep 13 Option 15.39 20,000 307,800 09/14/23
MCCLUSKI STEPHEN C Director Director Sep 13 Option 15.38 20,000 307,600 09/14/23
Lentini Renee PRIN. FIN & ACCTG... PRIN. FIN & ACCTG. OFF. Sep 12 Option 4.28 25,141 107,603 99,017 09/14/23
Coen Stacy Ann SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER Aug 09 Sell 14.2 100,210 1,422,982 10,960 08/11/23
Coen Stacy Ann SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER Aug 09 Option 4.92 100,210 493,033 111,170 08/11/23
Coen Stacy Ann SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER Aug 02 Sell 17.59 84,581 1,487,780 10,960 08/04/23
Coen Stacy Ann SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER Aug 02 Option 4.92 84,581 416,139 91,286 08/04/23
Enyedy Mark J CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Aug 02 Sell 17.29 3,007,554 52,000,609 553,270 08/04/23
Enyedy Mark J CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Aug 02 Option 4.97 3,119,375 15,503,294 1,545,667 08/04/23
Lentini Renee PRIN. FIN & ACCTG... PRIN. FIN & ACCTG. OFF. Aug 02 Sell 17.55 148,277 2,602,261 22,843 08/04/23
Lentini Renee PRIN. FIN & ACCTG... PRIN. FIN & ACCTG. OFF. Aug 02 Option 3.98 199,310 793,254 73,876 08/04/23
FOSTER DAVID G V.P.-Fin., Prin. Acc.. V.P.-Fin., Prin. Acctg. Off. Jan 04 Sell 6.38 11,052 70,512 37,912 01/04/21